PACA Nanoparticles for Cabazitaxel Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using chemotherapy are inadequate for certain cancer types and result in severe side effects, particularly with hydrophobic and poorly soluble therapeutic agents like cabazitaxel, which are difficult to deliver effectively to specific locations in the body.
Innovation Solution
A drug delivery system utilizing poly(alkyl cyanoacrylate) nanoparticles (PACA NPs) encapsulating cabazitaxel (CBZ) for intraperitoneal administration, which are produced via miniemulsion anionic polymerization and optionally PEGylated, allowing for targeted delivery and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat advanced cancer, then therapeutic effect is achieved, but severe side effects occur and efficacy is insufficient for certain cancer types
Solution Approach 1:
The patent segments the chemotherapy delivery system into nanoparticle carriers (PACA NPs) that encapsulate the drug, allowing selective accumulation at tumor sites through the EPR effect while sparing healthy tissues, thereby improving therapeutic efficacy and reducing side effects
Solution Approach 2:
The patent implements local quality by enabling high drug concentration accumulation specifically at the tumor microenvironment through nanoparticle targeting and EPR effect, while maintaining low drug concentrations in healthy tissues, thus achieving localized therapeutic action with reduced systemic toxicity
2Reliability
If hydrophobic therapeutic agents like cabazitaxel are administered, then potent cytostatic effect is achieved, but difficult delivery to specific locations occurs
Solution Approach 1:
The patent uses PACA nanoparticles as an intermediary carrier that solubilizes hydrophobic cabazitaxel molecules, enabling their transport through aqueous biological fluids and targeted delivery to peritoneal cavity tumors, thereby overcoming the solubility and delivery challenges of hydrophobic agents
Solution Approach 2:
The patent creates a composite drug delivery system combining hydrophobic cabazitaxel with amphiphilic PACA nanoparticle carriers, forming a stable nanocomposite that enables effective delivery of the hydrophobic agent to specific locations in the peritoneal cavity
3Ease of operation
If traditional intravenous administration is used, then systemic distribution is achieved, but high systemic toxicity occurs
Solution Approach 1:
The patent implements local quality by designing intraperitoneal nanoparticle administration that achieves high local drug concentrations in the peritoneal cavity tumors while minimizing systemic circulation and exposure, thereby reducing systemic toxicity compared to traditional intravenous administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves improved efficacy and reduced side effects by providing high local drug concentrations in the peritoneal cavity, effectively treating peritoneal carcinomatosis and other cancers with enhanced retention and reduced systemic toxicity compared to traditional intravenous administration.
Implementation Method 1
Taxanes present difficulties in formulation as medicines because they are poorly soluble in water
Implementation Method 2
anionic polymerization of an oil-in-water miniemulsion
Implementation Method 3
oil-in-water miniemulsion
Implementation Method 4
by utilizing a miniemulsion in combination with a particular class of polyalkylene glycol derivatives
Implementation Method 5
by benefiting from the enhanced permeability and retention (EPR) effect
Data Source
AI summary
Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.